Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SELLAS Life Sciences Group, Inc. | b86288exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 2)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 13, 2011
RXI PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 001-33958 | 20-8099512 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
60 Prescott Street,
Worcester, Massachusetts
01605
(Address of Principal Executive Offices) (Zip Code)
Worcester, Massachusetts
01605
Registrant’s telephone number, including area code: (508) 767-3861
Not Applicable
Former name or former address, if changed since last report
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
RXi Pharmaceuticals Corporation (“RXi”) files this Form 8-K/A (Amendment No. 2) to provide
certain pro forma financial information related to its acquisition of Apthera, Inc. (“Apthera”),
which closed on April 13, 2011. Reference is made to the Form 8-K filed by RXi on April 14, 2011,
as previously amended by the Form 8-K/A (Amendment No. 1) filed on April 15, 2011.
Item 9.01 Financial Statements and Exhibits
Pursuant to Article 8 of Regulation S-X, the following pro forma financial information is
included as Exhibit 99.1 to this Form 8-K/A and incorporated herein by reference:
| (a) | Pro Forma Financial Information Regarding Business Acquired |
| (i) | Unaudited pro forma condensed combined balance sheet as of December 31, 2010 |
| (ii) | Unaudited pro forma condensed combined statement of expenses for the year ended December 31, 2010 |
| (b) | Exhibits |
The following exhibit is filed as part of this Form 8/K/A.
| Exhibit | ||||
| No. | Description | |||
| 99.1 | Unaudited pro forma condensed combined financial information |
|||
1
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RXI PHARMACEUTICALS CORPORATION |
||||
| Date: May 4, 2011 | By: | /s/ Mark J. Ahn | ||
| Mark J. Ahn | ||||
| President and Chief Executive Officer | ||||
2
Index to Exhibits
| Exhibit | ||||
| No. | Description | |||
| 99.1 | Unaudited pro forma condensed combined financial information |
|||
3